Showing results (401-410 of 417) with videos related to

Sort By:
Pageof 42
Liver International : Official Journal of the International Association for the Study of the Liver|April 15, 2026
REACT Score, a Novel Scoring System, Improves the Prediction of Non-Elective Readmissions in Patients With Decompensated CirrhosisYolanda Sánchez-Torrijos, Ana Torres-Domínguez, Isabel Carmona, et al.
The American Journal of Gastroenterology|June 22, 2016
Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE StudyJoseph Ahn, Joseph K Lim, Hannah M Lee, et al.
Nature Medicine|February 9, 2026
Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedentsAbraham Shaked, Alex Sagar, Kim M Olthoff, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 19, 2016
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infectionRobert J Fontana, Robert S Brown, Ana Moreno-Zamora, et al.
Plos One|September 1, 2023
Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016Jessica Kim, Craig W Newcomb, Dean M Carbonari, et al.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Gastroenterology|November 9, 2024
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in CirrhosisNaoto Fujiwara, Camden Lopez, Tracey L Marsh, et al.
Gastroenterology|May 20, 2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseMichael Charlton, Gregory T Everson, Steven L Flamm, et al.
Pageof 42